Hengrui Pharma's 64 Oncology Research Findings Accepted for ESMO 2026

PUBT · 2d ago
Hengrui Pharma's 64 Oncology Research Findings Accepted for ESMO 2026
  • Hengrui Pharma will present 64 research findings at the ESMO Congress in Madrid, October 23-27, 2026.
  • Phase 3 HORIZON-Breast06 findings will assess HER2-targeted antibody-drug conjugate trastuzumab rezetecan in HER2-low advanced breast cancer.
  • HERON-Lung01 interim analyses will compare ruzaltatug rezetecan with platinum-based chemotherapy in EGFR-mutated advanced non-small-cell lung cancer progressing following EGFR-TKI treatment.
  • China accepted ruzaltatug rezetecan’s marketing application for review in July 2026; the drug also holds US FDA Fast Track designation.
  • Preliminary phase 2 results will evaluate HRS-4642 with chemotherapy, with or without adebrelimab, as perioperative treatment for KRAS G12D-mutant pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN76423) on October 20, 2026, and is solely responsible for the information contained therein.